{"id":20426,"date":"2025-01-31T13:17:37","date_gmt":"2025-01-31T18:17:37","guid":{"rendered":"https:\/\/thespanishmedia.com\/?p=20426"},"modified":"2025-01-31T13:17:37","modified_gmt":"2025-01-31T18:17:37","slug":"fda-aprueba-nuevo-analgesico-no-opioide-que-promete-reducir-el-riesgo-de-adiccion-y-sobredosis","status":"publish","type":"post","link":"https:\/\/thespanishmedia.com\/fr\/fda-aprueba-nuevo-analgesico-no-opioide-que-promete-reducir-el-riesgo-de-adiccion-y-sobredosis\/","title":{"rendered":"FDA aprueba nuevo analg\u00e9sico no opioide que promete reducir el riesgo de adicci\u00f3n y sobredosis"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">La Administraci\u00f3n de Alimentos y Medicamentos de Estados Unidos (FDA, por sus siglas en ingl\u00e9s) aprob\u00f3 un nuevo tipo de analg\u00e9sico dise\u00f1ado para tratar el dolor agudo sin los riesgos de adicci\u00f3n y sobredosis asociados con los opioides. El medicamento, llamado <\/span><i><span style=\"font-weight: 400;\">Journavx<\/span><\/i><span style=\"font-weight: 400;\"> y desarrollado por <\/span><i><span style=\"font-weight: 400;\">Vertex Pharmaceuticals<\/span><\/i><span style=\"font-weight: 400;\">, representa un hito en la b\u00fasqueda de alternativas seguras para el manejo del dolor.<\/span><\/p>\n<p><i><span style=\"font-weight: 400;\">Journavx<\/span><\/i><span style=\"font-weight: 400;\">, cuyo principio activo es la suzetrigina, funciona bloqueando las prote\u00ednas que transmiten las se\u00f1ales de dolor antes de que lleguen al cerebro. A diferencia de los opioides, que act\u00faan en los receptores cerebrales y pueden generar dependencia, este nuevo enfoque ofrece un alivio del dolor sin afectar otras funciones sensoriales.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">La aprobaci\u00f3n de la FDA se bas\u00f3 en dos estudios cl\u00ednicos realizados con m\u00e1s de 870 pacientes que sufr\u00edan dolor agudo tras cirug\u00edas de pie y abdomen. Los resultados mostraron que <\/span><i><span style=\"font-weight: 400;\">Journavx<\/span><\/i><span style=\"font-weight: 400;\"> proporcion\u00f3 un alivio significativo del dolor en comparaci\u00f3n con un placebo, aunque no super\u00f3 a una combinaci\u00f3n de opioides con acetaminof\u00e9n. Entre los efectos secundarios reportados se encuentran n\u00e1useas, estre\u00f1imiento, sarpullido y dolor de cabeza.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">El descubrimiento de suzetrigina tiene un origen inusual: una investigaci\u00f3n sobre una familia pakistan\u00ed cuyos miembros pod\u00edan caminar sobre brasas sin sentir dolor debido a una mutaci\u00f3n gen\u00e9tica. Inspirados por este fen\u00f3meno, los cient\u00edficos buscaron una manera de replicar el efecto en un medicamento seguro para el consumo humano.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">A pesar del entusiasmo por esta nueva opci\u00f3n terap\u00e9utica, el medicamento enfrenta desaf\u00edos. Un estudio reciente en pacientes con dolor cr\u00f3nico por ci\u00e1tica no demostr\u00f3 diferencias significativas con respecto al placebo, lo que podr\u00eda limitar su aplicaci\u00f3n en ciertos tipos de dolor prolongado. Sin embargo, <\/span><i><span style=\"font-weight: 400;\">Vertex Pharmaceuticals<\/span><\/i><span style=\"font-weight: 400;\"> planea continuar investigando su efectividad en otros tipos de dolor cr\u00f3nico, como la neuropat\u00eda diab\u00e9tica.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">El costo tambi\u00e9n podr\u00eda ser un factor determinante en su adopci\u00f3n. <\/span><i><span style=\"font-weight: 400;\">Vertex<\/span><\/i><span style=\"font-weight: 400;\"> ha fijado un precio mayorista de $15,50 por cada p\u00edldora de 50 mg y ha anunciado programas de asistencia para pacientes. A\u00fan est\u00e1 por verse cu\u00e1l ser\u00e1 la respuesta de las aseguradoras y qu\u00e9 impacto tendr\u00e1 en la accesibilidad del medicamento.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">La aprobaci\u00f3n de <\/span><i><span style=\"font-weight: 400;\">Journavx<\/span><\/i><span style=\"font-weight: 400;\"> llega en un momento crucial en la lucha contra la crisis de los opioides, que ha cobrado la vida de miles de personas en Estados Unidos. Seg\u00fan datos gubernamentales, cada a\u00f1o se emiten aproximadamente 80 millones de recetas para tratar el dolor moderado a severo, y la mitad de ellas corresponden a opioides.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">M\u00e9dicos y especialistas en el manejo del dolor han recibido con optimismo la llegada de <\/span><i><span style=\"font-weight: 400;\">Journavx<\/span><\/i><span style=\"font-weight: 400;\">, aunque advierten que no ser\u00e1 la soluci\u00f3n \u00fanica para el problema del dolor y la adicci\u00f3n.\u00a0<\/span><\/p>\n<p><b>Redacci\u00f3n de: <\/b><span style=\"font-weight: 400;\">Karen Rodr\u00edguez A.<\/span><\/p>","protected":false},"excerpt":{"rendered":"<p>La Administraci\u00f3n de Alimentos y Medicamentos de Estados Unidos (FDA, por sus siglas en ingl\u00e9s) aprob\u00f3 un nuevo tipo de analg\u00e9sico dise\u00f1ado para tratar el dolor agudo sin los riesgos de adicci\u00f3n y sobredosis asociados con los opioides. El medicamento, llamado Journavx y desarrollado por Vertex Pharmaceuticals, representa un hito en la b\u00fasqueda de alternativas [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":20432,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_glsr_average":0,"_glsr_ranking":0,"_glsr_reviews":0,"footnotes":""},"categories":[6],"tags":[5123,5124,4159,5125,5126,5127,5128,5129,5130,5131,224,2615,5132,271,204],"class_list":["post-20426","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notas-para-curiosos","tag-adiccion","tag-analgesico","tag-cuidadodesalud","tag-fda","tag-innovacionmedica","tag-medicamentosseguros","tag-noopioide","tag-nuevomedicamento","tag-prevencionadiccion","tag-riesgodesobredosis","tag-saludpublica","tag-saludybienestar","tag-tratamientodolor","tag-medicamentos","tag-salud"],"blocksy_meta":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FDA aprueba nuevo analg\u00e9sico no opioide que promete reducir el riesgo de adicci\u00f3n y sobredosis - The Spanish Media<\/title>\n<meta name=\"description\" content=\"La Administraci\u00f3n de Alimentos y Medicamentos de Estados Unidos (FDA, por sus siglas en ingl\u00e9s) aprob\u00f3 un nuevo tipo de analg\u00e9sico dise\u00f1ado para tratar el dolor agudo sin los riesgos de adicci\u00f3n y sobredosis asociados con los opioides.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/thespanishmedia.com\/fr\/fda-aprueba-nuevo-analgesico-no-opioide-que-promete-reducir-el-riesgo-de-adiccion-y-sobredosis\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA aprueba nuevo analg\u00e9sico no opioide que promete reducir el riesgo de adicci\u00f3n y sobredosis - The Spanish Media\" \/>\n<meta property=\"og:description\" content=\"La Administraci\u00f3n de Alimentos y Medicamentos de Estados Unidos (FDA, por sus siglas en ingl\u00e9s) aprob\u00f3 un nuevo tipo de analg\u00e9sico dise\u00f1ado para tratar el dolor agudo sin los riesgos de adicci\u00f3n y sobredosis asociados con los opioides.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/thespanishmedia.com\/fr\/fda-aprueba-nuevo-analgesico-no-opioide-que-promete-reducir-el-riesgo-de-adiccion-y-sobredosis\/\" \/>\n<meta property=\"og:site_name\" content=\"The Spanish Media\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-31T18:17:37+00:00\" \/>\n<meta name=\"author\" content=\"The Spanish Media\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"The Spanish Media\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/thespanishmedia.com\\\/fda-aprueba-nuevo-analgesico-no-opioide-que-promete-reducir-el-riesgo-de-adiccion-y-sobredosis\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/thespanishmedia.com\\\/fda-aprueba-nuevo-analgesico-no-opioide-que-promete-reducir-el-riesgo-de-adiccion-y-sobredosis\\\/\"},\"author\":{\"name\":\"The Spanish Media\",\"@id\":\"https:\\\/\\\/thespanishmedia.com\\\/#\\\/schema\\\/person\\\/cdfd443208fa68f9cec21cb44a66c134\"},\"headline\":\"FDA aprueba nuevo analg\u00e9sico no opioide que promete reducir el riesgo de adicci\u00f3n y sobredosis\",\"datePublished\":\"2025-01-31T18:17:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/thespanishmedia.com\\\/fda-aprueba-nuevo-analgesico-no-opioide-que-promete-reducir-el-riesgo-de-adiccion-y-sobredosis\\\/\"},\"wordCount\":499,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/thespanishmedia.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/thespanishmedia.com\\\/fda-aprueba-nuevo-analgesico-no-opioide-que-promete-reducir-el-riesgo-de-adiccion-y-sobredosis\\\/#primaryimage\"},\"thumbnailUrl\":\"\",\"keywords\":[\"#Adicci\u00f3n\",\"#Analg\u00e9sico\",\"#CuidadoDeSalud\",\"#FDA\",\"#Innovaci\u00f3nM\u00e9dica\",\"#MedicamentosSeguros\",\"#NoOpioide\",\"#NuevoMedicamento\",\"#Prevenci\u00f3nAdicci\u00f3n\",\"#RiesgoDeSobredosis\",\"#SaludP\u00fablica\",\"#SaludYBienestar\",\"#TratamientoDolor\",\"medicamentos\",\"salud\"],\"articleSection\":[\"Notas para Curiosos\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/thespanishmedia.com\\\/fda-aprueba-nuevo-analgesico-no-opioide-que-promete-reducir-el-riesgo-de-adiccion-y-sobredosis\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/thespanishmedia.com\\\/fda-aprueba-nuevo-analgesico-no-opioide-que-promete-reducir-el-riesgo-de-adiccion-y-sobredosis\\\/\",\"url\":\"https:\\\/\\\/thespanishmedia.com\\\/fda-aprueba-nuevo-analgesico-no-opioide-que-promete-reducir-el-riesgo-de-adiccion-y-sobredosis\\\/\",\"name\":\"FDA aprueba nuevo analg\u00e9sico no opioide que promete reducir el riesgo de adicci\u00f3n y sobredosis - The Spanish Media\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/thespanishmedia.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/thespanishmedia.com\\\/fda-aprueba-nuevo-analgesico-no-opioide-que-promete-reducir-el-riesgo-de-adiccion-y-sobredosis\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/thespanishmedia.com\\\/fda-aprueba-nuevo-analgesico-no-opioide-que-promete-reducir-el-riesgo-de-adiccion-y-sobredosis\\\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2025-01-31T18:17:37+00:00\",\"description\":\"La Administraci\u00f3n de Alimentos y Medicamentos de Estados Unidos (FDA, por sus siglas en ingl\u00e9s) aprob\u00f3 un nuevo tipo de analg\u00e9sico dise\u00f1ado para tratar el dolor agudo sin los riesgos de adicci\u00f3n y sobredosis asociados con los opioides.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/thespanishmedia.com\\\/fda-aprueba-nuevo-analgesico-no-opioide-que-promete-reducir-el-riesgo-de-adiccion-y-sobredosis\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/thespanishmedia.com\\\/fda-aprueba-nuevo-analgesico-no-opioide-que-promete-reducir-el-riesgo-de-adiccion-y-sobredosis\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/thespanishmedia.com\\\/fda-aprueba-nuevo-analgesico-no-opioide-que-promete-reducir-el-riesgo-de-adiccion-y-sobredosis\\\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/thespanishmedia.com\\\/fda-aprueba-nuevo-analgesico-no-opioide-que-promete-reducir-el-riesgo-de-adiccion-y-sobredosis\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/thespanishmedia.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA aprueba nuevo analg\u00e9sico no opioide que promete reducir el riesgo de adicci\u00f3n y sobredosis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/thespanishmedia.com\\\/#website\",\"url\":\"https:\\\/\\\/thespanishmedia.com\\\/\",\"name\":\"The Spanish Media\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/thespanishmedia.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/thespanishmedia.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/thespanishmedia.com\\\/#organization\",\"name\":\"The Spanish Media\",\"url\":\"https:\\\/\\\/thespanishmedia.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/thespanishmedia.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/thespanishmedia.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/Logo-Horizontal.png\",\"contentUrl\":\"https:\\\/\\\/thespanishmedia.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/Logo-Horizontal.png\",\"width\":1840,\"height\":720,\"caption\":\"The Spanish Media\"},\"image\":{\"@id\":\"https:\\\/\\\/thespanishmedia.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/thespanishmedia.com\\\/#\\\/schema\\\/person\\\/cdfd443208fa68f9cec21cb44a66c134\",\"name\":\"The Spanish Media\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4a6f15b35b39a16d5773702f6e938298774ef701109a0e7fb8d3a3e34f260f3a?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4a6f15b35b39a16d5773702f6e938298774ef701109a0e7fb8d3a3e34f260f3a?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4a6f15b35b39a16d5773702f6e938298774ef701109a0e7fb8d3a3e34f260f3a?s=96&d=mm&r=g\",\"caption\":\"The Spanish Media\"},\"url\":\"https:\\\/\\\/thespanishmedia.com\\\/fr\\\/author\\\/media\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA aprueba nuevo analg\u00e9sico no opioide que promete reducir el riesgo de adicci\u00f3n y sobredosis - The Spanish Media","description":"La Administraci\u00f3n de Alimentos y Medicamentos de Estados Unidos (FDA, por sus siglas en ingl\u00e9s) aprob\u00f3 un nuevo tipo de analg\u00e9sico dise\u00f1ado para tratar el dolor agudo sin los riesgos de adicci\u00f3n y sobredosis asociados con los opioides.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/thespanishmedia.com\/fr\/fda-aprueba-nuevo-analgesico-no-opioide-que-promete-reducir-el-riesgo-de-adiccion-y-sobredosis\/","og_locale":"fr_FR","og_type":"article","og_title":"FDA aprueba nuevo analg\u00e9sico no opioide que promete reducir el riesgo de adicci\u00f3n y sobredosis - The Spanish Media","og_description":"La Administraci\u00f3n de Alimentos y Medicamentos de Estados Unidos (FDA, por sus siglas en ingl\u00e9s) aprob\u00f3 un nuevo tipo de analg\u00e9sico dise\u00f1ado para tratar el dolor agudo sin los riesgos de adicci\u00f3n y sobredosis asociados con los opioides.","og_url":"https:\/\/thespanishmedia.com\/fr\/fda-aprueba-nuevo-analgesico-no-opioide-que-promete-reducir-el-riesgo-de-adiccion-y-sobredosis\/","og_site_name":"The Spanish Media","article_published_time":"2025-01-31T18:17:37+00:00","author":"The Spanish Media","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"The Spanish Media","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/thespanishmedia.com\/fda-aprueba-nuevo-analgesico-no-opioide-que-promete-reducir-el-riesgo-de-adiccion-y-sobredosis\/#article","isPartOf":{"@id":"https:\/\/thespanishmedia.com\/fda-aprueba-nuevo-analgesico-no-opioide-que-promete-reducir-el-riesgo-de-adiccion-y-sobredosis\/"},"author":{"name":"The Spanish Media","@id":"https:\/\/thespanishmedia.com\/#\/schema\/person\/cdfd443208fa68f9cec21cb44a66c134"},"headline":"FDA aprueba nuevo analg\u00e9sico no opioide que promete reducir el riesgo de adicci\u00f3n y sobredosis","datePublished":"2025-01-31T18:17:37+00:00","mainEntityOfPage":{"@id":"https:\/\/thespanishmedia.com\/fda-aprueba-nuevo-analgesico-no-opioide-que-promete-reducir-el-riesgo-de-adiccion-y-sobredosis\/"},"wordCount":499,"commentCount":0,"publisher":{"@id":"https:\/\/thespanishmedia.com\/#organization"},"image":{"@id":"https:\/\/thespanishmedia.com\/fda-aprueba-nuevo-analgesico-no-opioide-que-promete-reducir-el-riesgo-de-adiccion-y-sobredosis\/#primaryimage"},"thumbnailUrl":"","keywords":["#Adicci\u00f3n","#Analg\u00e9sico","#CuidadoDeSalud","#FDA","#Innovaci\u00f3nM\u00e9dica","#MedicamentosSeguros","#NoOpioide","#NuevoMedicamento","#Prevenci\u00f3nAdicci\u00f3n","#RiesgoDeSobredosis","#SaludP\u00fablica","#SaludYBienestar","#TratamientoDolor","medicamentos","salud"],"articleSection":["Notas para Curiosos"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/thespanishmedia.com\/fda-aprueba-nuevo-analgesico-no-opioide-que-promete-reducir-el-riesgo-de-adiccion-y-sobredosis\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/thespanishmedia.com\/fda-aprueba-nuevo-analgesico-no-opioide-que-promete-reducir-el-riesgo-de-adiccion-y-sobredosis\/","url":"https:\/\/thespanishmedia.com\/fda-aprueba-nuevo-analgesico-no-opioide-que-promete-reducir-el-riesgo-de-adiccion-y-sobredosis\/","name":"FDA aprueba nuevo analg\u00e9sico no opioide que promete reducir el riesgo de adicci\u00f3n y sobredosis - The Spanish Media","isPartOf":{"@id":"https:\/\/thespanishmedia.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/thespanishmedia.com\/fda-aprueba-nuevo-analgesico-no-opioide-que-promete-reducir-el-riesgo-de-adiccion-y-sobredosis\/#primaryimage"},"image":{"@id":"https:\/\/thespanishmedia.com\/fda-aprueba-nuevo-analgesico-no-opioide-que-promete-reducir-el-riesgo-de-adiccion-y-sobredosis\/#primaryimage"},"thumbnailUrl":"","datePublished":"2025-01-31T18:17:37+00:00","description":"La Administraci\u00f3n de Alimentos y Medicamentos de Estados Unidos (FDA, por sus siglas en ingl\u00e9s) aprob\u00f3 un nuevo tipo de analg\u00e9sico dise\u00f1ado para tratar el dolor agudo sin los riesgos de adicci\u00f3n y sobredosis asociados con los opioides.","breadcrumb":{"@id":"https:\/\/thespanishmedia.com\/fda-aprueba-nuevo-analgesico-no-opioide-que-promete-reducir-el-riesgo-de-adiccion-y-sobredosis\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/thespanishmedia.com\/fda-aprueba-nuevo-analgesico-no-opioide-que-promete-reducir-el-riesgo-de-adiccion-y-sobredosis\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/thespanishmedia.com\/fda-aprueba-nuevo-analgesico-no-opioide-que-promete-reducir-el-riesgo-de-adiccion-y-sobredosis\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/thespanishmedia.com\/fda-aprueba-nuevo-analgesico-no-opioide-que-promete-reducir-el-riesgo-de-adiccion-y-sobredosis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/thespanishmedia.com\/"},{"@type":"ListItem","position":2,"name":"FDA aprueba nuevo analg\u00e9sico no opioide que promete reducir el riesgo de adicci\u00f3n y sobredosis"}]},{"@type":"WebSite","@id":"https:\/\/thespanishmedia.com\/#website","url":"https:\/\/thespanishmedia.com\/","name":"The Spanish Media","description":"","publisher":{"@id":"https:\/\/thespanishmedia.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/thespanishmedia.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/thespanishmedia.com\/#organization","name":"The Spanish Media","url":"https:\/\/thespanishmedia.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/thespanishmedia.com\/#\/schema\/logo\/image\/","url":"https:\/\/thespanishmedia.com\/wp-content\/uploads\/2026\/08\/Logo-Horizontal.png","contentUrl":"https:\/\/thespanishmedia.com\/wp-content\/uploads\/2026\/08\/Logo-Horizontal.png","width":1840,"height":720,"caption":"The Spanish Media"},"image":{"@id":"https:\/\/thespanishmedia.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/thespanishmedia.com\/#\/schema\/person\/cdfd443208fa68f9cec21cb44a66c134","name":"The Spanish Media","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/4a6f15b35b39a16d5773702f6e938298774ef701109a0e7fb8d3a3e34f260f3a?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/4a6f15b35b39a16d5773702f6e938298774ef701109a0e7fb8d3a3e34f260f3a?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4a6f15b35b39a16d5773702f6e938298774ef701109a0e7fb8d3a3e34f260f3a?s=96&d=mm&r=g","caption":"The Spanish Media"},"url":"https:\/\/thespanishmedia.com\/fr\/author\/media\/"}]}},"_links":{"self":[{"href":"https:\/\/thespanishmedia.com\/fr\/wp-json\/wp\/v2\/posts\/20426","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thespanishmedia.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thespanishmedia.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thespanishmedia.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/thespanishmedia.com\/fr\/wp-json\/wp\/v2\/comments?post=20426"}],"version-history":[{"count":0,"href":"https:\/\/thespanishmedia.com\/fr\/wp-json\/wp\/v2\/posts\/20426\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/thespanishmedia.com\/fr\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/thespanishmedia.com\/fr\/wp-json\/wp\/v2\/media?parent=20426"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thespanishmedia.com\/fr\/wp-json\/wp\/v2\/categories?post=20426"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thespanishmedia.com\/fr\/wp-json\/wp\/v2\/tags?post=20426"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}